— Hutchings A.
J Med Ethics. 2022; 48:99-100.
doi:10.1136/medethics-2022-108128
Related articles
Future-Proofing HTA: the case for flexibility in assessment frameworks
Rare Diseases28/05/2026
Why orphan medicines remain out of reach in low- and middle-income countries – and what can be done
Rare Diseases27/02/2026
Rare disease policy in high-income countries: An overview of achievements, challenges, and solutions
European PolicyRare DiseasesUS Policy10/05/2025
What do the new Medicare negotiations mean for pipeline orphan therapies?
Rare DiseasesUS Policy04/03/2025